ArticleInternational journal of radiation oncology, biology, physics2026
Development and Dosimetric Characterization of an In Vitro Benchtop Americium 241 Alpha Irradiator Platform.
Article in International journal of radiation oncology, biology, physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
purposeTo expand preclinical efforts aimed at understanding the unique radiobiology of high linear energy transfer alpha particles and their implications for cancer therapy, robust, accessible, and high-throughput in vitro alpha irradiation platforms are needed. Such platforms must be extensively characterized and validated to ensure rigor and reproducibility. Here, we describe the construction and dosimetric characterization of a benchtop in vitro alpha irradiation platform using an americium 241 ( METHODS AND MATERIALS: A square foil with embedded
resultsThe
conclusionsWe established a turnkey, low-cost in vitro alpha irradiation platform suitable for high-throughput preclinical studies. The homogeneity, alpha particle energy spectra, absorbed dose, and dose rate were characterized and validated through direct measurements. Given the approximately 432-year half-life of
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.